Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Additional Factors in Considering Patent Foramen Ovale Closure to Prevent Recurrent Ischemic Stroke—Reply

Additional Factors in Considering Patent Foramen Ovale Closure to Prevent Recurrent Ischemic... Letters Meeting Presentation: This paper was presented at the 2018 American losses to follow-up of 1.2% and 0.4%, respectively, had opposite Academy of Neurology Annual Meeting; April 27, 2018; Los Angeles, California. 3 results. CLOSURE had 12 strokes in the device group and 13 in Additional Contributions: John Schmeling, BS (Department of Laboratory the medical group during a 2-year follow-up (hazard ratio, 0.90; Medicine and Pathology, Mayo Clinic, Rochester, Minnesota), provided 95%CI,0.41–1.98;P = .79).CLOSEhad0stokesinthedevicegroup technical support; Mary Curtis (Department of Laboratory Medicine and and 14 in the medical group during a mean (SD) of 5.3 (2.0) years’ Pathology, Mayo Clinic) secretarial assistance, Jessica Sagan, MA (Center for MS follow-up (hazard ratio, 0.03; 95% CI, 0.0-0.26;P < .001). Even and Autoimmune Neurology, Mayo Clinic), study coordination, and Sarah M. Jenkins, MS (Department of Health Sciences Research, Mayo Clinic), statistical ifweaccepttheCLOSEresultsasvalidbecausethestudyuseddif- analysis. Majed Masoud, MD (Department of Neurology, Mayo Clinic), W. Oliver ferent devices and more stringent eligibility criteria, most of the Tobin, MB, BCh, BAO, PhD (Department of Neurology, Center for MS and potentially preventable strokes in the CLOSE medical group were Autoimmune Neurology, Mayo Clinic), Mark Keegan, MD (Department of very mild. In a written conversation with J. L. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Neurology American Medical Association

Additional Factors in Considering Patent Foramen Ovale Closure to Prevent Recurrent Ischemic Stroke—Reply

JAMA Neurology , Volume 75 (7) – Jul 14, 2018

Loading next page...
 
/lp/american-medical-association/additional-factors-in-considering-patent-foramen-ovale-closure-to-9qWyeUsLjC

References (1)

Publisher
American Medical Association
Copyright
Copyright 2018 American Medical Association. All Rights Reserved.
ISSN
2168-6149
eISSN
2168-6157
DOI
10.1001/jamaneurol.2018.1022
Publisher site
See Article on Publisher Site

Abstract

Letters Meeting Presentation: This paper was presented at the 2018 American losses to follow-up of 1.2% and 0.4%, respectively, had opposite Academy of Neurology Annual Meeting; April 27, 2018; Los Angeles, California. 3 results. CLOSURE had 12 strokes in the device group and 13 in Additional Contributions: John Schmeling, BS (Department of Laboratory the medical group during a 2-year follow-up (hazard ratio, 0.90; Medicine and Pathology, Mayo Clinic, Rochester, Minnesota), provided 95%CI,0.41–1.98;P = .79).CLOSEhad0stokesinthedevicegroup technical support; Mary Curtis (Department of Laboratory Medicine and and 14 in the medical group during a mean (SD) of 5.3 (2.0) years’ Pathology, Mayo Clinic) secretarial assistance, Jessica Sagan, MA (Center for MS follow-up (hazard ratio, 0.03; 95% CI, 0.0-0.26;P < .001). Even and Autoimmune Neurology, Mayo Clinic), study coordination, and Sarah M. Jenkins, MS (Department of Health Sciences Research, Mayo Clinic), statistical ifweaccepttheCLOSEresultsasvalidbecausethestudyuseddif- analysis. Majed Masoud, MD (Department of Neurology, Mayo Clinic), W. Oliver ferent devices and more stringent eligibility criteria, most of the Tobin, MB, BCh, BAO, PhD (Department of Neurology, Center for MS and potentially preventable strokes in the CLOSE medical group were Autoimmune Neurology, Mayo Clinic), Mark Keegan, MD (Department of very mild. In a written conversation with J. L.

Journal

JAMA NeurologyAmerican Medical Association

Published: Jul 14, 2018

There are no references for this article.